Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study

The Lancet 2026

View at publisher
Authors: Tania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, Dylan Trundell, Thomas Kustermann, Tanya Simuni, Kenneth Marek, Nicola Pavese, Klaus Seppi, Fabrizio Stocchi, Ronald B Postuma, Nathalie Pross
+9 more Annabelle Monnet, Gesine Respondek, Valerie Schlegel, Lauren Boak, Loes Rutten-Jacobs, Geoffrey A. Kerchner, Patrik Brundin, Hanno Svoboda, Azad Bonni
DOI: 10.1016/s0140-6736(26)00865-2
Cited by: 4
References: 21

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Multiple Sclerosis Research Studies Protease and Inhibitor Mechanisms

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
407
Issue
10544
Pages
2227–2240
Publication date
1 May 2026
Language
EN